Roche’s Gazyvaro Is Fifth Drug To Enter UK Cancer Drugs Fund
Executive Summary
Roche’s Gazyvaro is the fifth drug to be recommended by UK HTA body NICE for use on an interim fund that gives manufacturers more time to gather evidence to prove their drugs are cost-effective and win long-term funding on the National Health Service.